Kucers' the Use of Antibiotics (Print and Ebook Bundle)

Summary:

'I am unaware of any textbook which provides such comprehensive coverage of the field and doubt that this work will be surpassed in the foreseeable future, if ever!'

From the foreword by Robert C. Moellering, Jr., M.D, Shields Warren-Mallinckrodt Professor of Medical Research, Harvard Medical School, USA

• Written by a top international editorial team
• Extensively updated to include new, existing and emerging drugs
• Divided into 4 sections, 258 chapters and presented in 2-volumes
• Presented and packaged in 2-volumes plus an e-book

Kucers' The Use of Antibiotics is the leading major reference work in this vast and rapidly developing field. More than doubled in length compared to the fifth edition, the sixth edition comprises 3000 pages over 2-volumes in order to cover all new and existing therapies, and emerging drugs not yet fully licensed.

Concentrating on the treatment of infectious diseases, the content is divided into 4 sections: antibiotics, anti-fungal drugs,anti-parasitic drugs and anti-viral drugs, and is highly structured for ease of reference.Within each section, each chapter is structured to cover susceptibility, formulations and dosing (adult and paediatric), pharmacokinetics and pharmacodynamics, toxicity and drug distribution, detailed discussion regarding clinical uses, a feature unique to this title.

Compiled by an expanded team of internationally renowned and respected editors, with a vast number of contributors spanning Europe, Africa, Asia, Australia, South America, the US and Canada, the sixth edition adopts a truly global approach. It will remain invaluable for anyone using antimicrobial agents in their clinical practice and provides in a systematic and concise manner all the information required when treating infections requiring antimicrobial therapy.

Now Kucers' The Use of Antibiotics is available free to purchasers of the books as an electronic version on line or on your desktop:

• · It provides access to the entire 2-volume print material
• · It is fully searchable, so you can find the relevant information you need quickly
• · Live references are linked to PubMed referring you to the latest journal material
• · Customise the contents - you can highlight sections and make notes
• · Comments can be shared with colleagues/tutors for discussion, teaching and learning
• · The text can also be reflowed for ease of reading
• · Text and illustrations copied will be automatically referenced to Kucers' The Use of Antibiotics
• · THE essential reference to this vast, and rapidly developing field
• · Highly structured for ease of reference
• · Covers more than 350 individal antimicrobial agents, more than twice as many as the preceding edition
• · International team of highly respected authors and editors ensures a truly global approach

Reviews:

In keeping with its well-earned reputation as the leading and absolute authority on antibiotics, Kucers' remains a must-have for infectious diseases clinicians.
Clinical Infectious Disease 2011

This sixth edition of Kucers' The Use of Antibiotics is one of the most updated comprehensive compendiums on this subject. The book is a must in all hospitals and medical libraries.
Expert Rev. Anti Infect. Ther 2011

Table of Contents:

ANTIBIOTICS

• PART 1 - Penicillins and Related Drugs
• Benzylpenicillin (Penicillin G)
• Phenoxypenicillins
• Ampicillin, Amoxicillin and other Ampicillin-like penicillins
• Methicillin
• Isoxazolyl penicillins: Oxacillin, cloxacillin, dicloxacillin & flucloxacillin
• Nafcillin
• Carbenicillin, Carindacillin, Carfecillin & Ticarcillin
• Mezlocillin, Azlocillin, Apalcillin & Piperacillin
• Mecillinam (Amdinocillin) & Pivmecillinam
• Temocillin
• Beta-lactamase inhibitors and combinations:
• Clavulanic Acid
• Sulbactam
• Tazobactam and Brobactam
• Co-amoxiclav (amoxycillin-clavulanic acid)
• Ampicillin-sulbactam
• Ticarcillin-clavulanic acid
• Piperacillin-tazobactam

• PART 2 - Cephalosporins and Related Drugs n=18
• Cephalothin and Cefazolin
• Cephalexin
• Cephadroxil, Cephaloridine, Cephacetrile, Cephapirin, Cephradine and other rarely used first-generation cephalosporins
• Cefaclor, cefprozil and loracarbef
• Cefuroxime
• Cefotiam, Cefuzonam, Cefamandole, Cefonicid and Ceforanide
• Cefoxitin, cefotetan and other cephamycins (cefmetazole and flomoxef)
• Cefoperazone and cefoperazone-sulbactam
• Cefotaxime
• Ceftriaxone
• Ceftizoxime, cefdinir, cefditoren, cefpodoxime, ceftibuten, cefsulodin and cefpiramide
• Cefixime
• Ceftazidime
• Cefpirome
• Cefepime
• Ceftaroline
• Ceftobiprole
• Aztreonam

• PART 3 – Carbapenems n=9
• Imipenem
• Meropenem
• Doripenem
• Ertapenem
• Biapenem
• Faropenem
• Panipenem
• Ritapenem
• Sulopenem

• PART 4 - Glycopeptides and Lipopeptides
• Vancomycin
• Teicoplanin
• Daptomycin
• Oritavancin
• Dalbavancin
• Telavancin
• Ramoplanin

• PART 5 - Aminoglycosides
• Kanamycin
• Gentamicin
• Tobramycin
• Amikacin
• Sisomicin and Netilmicin
• Isepamicin
• Neomycin

• PART 6 – Macrolides and Ketolides
• Erythromycin
• Roxithromycin
• Clarithromycin
• Azithromycin
• Josamycin and Rosaramicin
• Telithromycin
• Cethromycin

• PART 7 – Tetracyclines and related drugs
• Tetracycline
• Doxycycline
• Minocycline
• Tigecycline

• PART 8 – Other antibiotics
• Linezolid
• Quinupristin-dalfopristin
• Pristinamycin
• Fosfomycin
• Fusidic acid (Fusidate sodium)
• Polymyxins and Colistin
• Novobiocin
• Bacitracin and Gramicidin
• Mupirocin
• Clindamycin and Lincomycin
• Chloramphenicol and Thiamphenicol
• Spectinomycin

• PART 9 – Anti-folate agents and other synthetic antibacterials
• Sulfonamides
• Trimethoprim, Co-trimoxazole (Co-T) & related agents
• Pyrimethamine
• Dapsone
• Trimetrexate
• Iclaprim
• Nitrofurans: Nitrofurazone, Furazolidone & Nitrofurantoin
• Methenamine Mandelate & Methenamine Hippurate

• PART 10 – Nitroimidazoles
• Metronidazole
• Tinidazole

• PART 11 – Quinolones and fluoroquinolones
• Nalidixic Acid & Other Older Quinolones
• Ciprofloxacin
• Norfloxacin
• Ofloxacin
• Levofloxacin
• Moxifloxacin
• Gatifloxacin
• Garenoxacin
• Gemifloxacin
• Sitafloxacin
• Enoxacin
• Pefloxacin
• Sparfloxacin
• Lomefloxacin
• Rufloxacin
• Tosufloxacin
• Fleroxacin
• Newer, discontinued fluoroquinolones: Temafloxacin, Trovafloxacin, Grepafloxacin and Clinafloxacin

• PART 12 – Anti-Tuberculous Drugs
• Isoniazid
• Ethambutol
• Pyrazinamide
• Rifampicin (Rifampin)
• Rifabutin
• Rifaximin
• Rifapentine
• Streptomycin
• Para-aminosalicylic Acid (PAS)
• Ethionamide and prothionamide
• Thiacetazone
• Capreomycin
• Cycloserine
• Viomycin

ANTI-FUNGAL DRUGS

• PART 1 - Polyenes
• Amphotericin B (AMB): Deoxycholate & Lipid Formulations
• Nystatin
• Natamycin (Pimaricin)

• PART 2 – Echinocandins, Allylamines and Benzylamine derivatives
• Echinocandins – Caspofungin, Anidulafungin & Micafungin
• Terbinafine
• Butenafine
• Naftifine

• PART 3 – Systemic Azoles
• Ketoconazole
• Fluconazole
• Itraconazole
• Miconazole
• Voriconazole
• Posaconazole
• Ravuconazole
• Albaconazole
• Isavuconazole

• PART 4 – Topical Azoles
• Bifonazole
• Butoconazole
• Clotrimazole
• Croconazole
• Eberconazole
• Econazole
• Enilconazole
• Fenticonazole
• Flutrimazole
• Isoconazole
• Lanoconazole
• Neticonazole
• Oxiconazole
• Sertaconazole
• Sulconazole
• Terconazole
• Tioconazole
• KP-103

• PART 5 – Topical agents – Thiocarbamates, Hydroxypyridones and Morpholine
• Tolnaftate
• Amorolfine
• Ciclopirox
• Rilopirox

• PART 6 – Other antifungal agents and new agents in development
• Flucytosine (5-Fluorocytosine; 5-FC)
• Griseofulvin
• Haloprogin
• New agents in development – Nikkomycin Z, CAY-1, Sodarins, Butenolides, Enfungumab, Inositol phosphoceramide synthase inhibitors

ANTI-PARASITIC DRUGS

• PART 1 – Anti-malarial agents
• Chloroquine
• Amodiaquine
• Quinine and quinidine
• Mefloquine
• Halofantrine
• Lumefantrine
• Primaquine
• Piperaquine
• Tafenoquine
• Atovaquone
• Proguanil & chloroproguanil
• Artemisinins

• PART 2 - Agents active against Intestinal and Intra-abdominal Protozoa
• Iodoquinol & Quinacrine
• Fumagillin
• Furazolidone (Furazolidine)
• Diloxanide furoate
• Spiramycin
• Nitazoxanide
• Paromomycin

• PART 3 - Agents active against American Trypanosomiasis
• Benznidazole
• Nifurtimox

• PART 4 - Agents active against African Trypanosomiasis
• Suramin
• Melarsoprol
• Eflornithine

• PART 5 – Agents active against leishmania and other pathogens
• Pentamidine
• Antimonial agents
• Miltefosine

• PART 6 - Agents active against Helminths
• Albendazole
• Mebendazole
• Thiabendazole
• Triclabendazole
• Ivermectin
• Diethylcarbamazine (DEC)
• Pyrantel pamoate
• Praziquantel
• Oxamniquine
• Metrifonate
• Niclosamide

• PART 7 - Agents active against Ectoparasites
• Permethrin
• Piperonyl butoxide
• Lindane
• Malathion
• Crotamiton

ANTI-VIRAL DRUGS

• PART 1 - Agents active against Herpesviruses
• Aciclovir
• Valaciclovir
• Famciclovir & Penciclovir
• Ganciclovir & Valganciclovir
• Cidofovir
• Vidarabine
• Foscarnet
• Maribavir
• Trifluridine (Trifluorothymidine)
• Idoxuridine
• Fomivirsen

• PART 2 - Agents active against Human Immunodeficiency Virus
• 2a - Inhibitors of Reverse Transcriptase
• Zidovudine
• Didanosine
• Zalcitabine
• Lamivudine
• Stavudine (d4T)
• Abacavir
• Emtricitabine
• Tenofovir
• Amdoxovir
• Apricitabine
• 2b – Non-Nucleoside Reverse Transcriptase inhibitors (NNRTIs)
• Nevirapine
• Efavirenz
• Delavirdine
• Etravirine
• Rilpirivine
• 2c - Inhibitors of HIV Protease
• Saquinavir
• Ritonavir
• Indinavir
• Nelfinavir
• Lopinavir
• Amprenavir and fosamprenavir
• Darunavir
• Atazanavir
• Tipranavir
• 2d - Other Anti-HIV Agents
• Enfuvirtide
• Maraviroc
• Raltegravir & other HIV integrase inibitors

• Part 3 - Agents active against Hepatitis viruses
• Entecavir
• Adefovir dipivoxil
• Telbivudine
• Torcitabine & Valtorcitabine
• Clevudine
• Ribavirin & Viramidine
• Pegylated Interferon Alfa
• Protease and polymerase inhibitors for the treatment of hepatitis C virus infection

• Part 4 - Agents active against Respiratory viruses
• Amantadine & Rimantadine
• Zanamivir and Polymeric Zanamivir Conjugates
• Oseltamivir
• Peramivir

About the Author(s):

M Lindsay Grayson MB BS MD MSC FRACP FRCP FAFPHM
Professor of Medicine and Director, Infectious Disease and Microbiology Departments, Austin Health Department of Epidemiology and Preventative Medicine, Monash University Department of Medicine, University of Melbourne, Melbourne, Australia

Section Editors: Suzanne M Crowe, James S McCarthy, John Mills, Johan W Mouton, S Ragnar Norrby, David L Paterson, Michael A Pfaller